XML 59 R50.htm IDEA: XBRL DOCUMENT
v3.23.3

Related Party Transactions (Details) |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | ---
Apr. 26, 2016 $ / shares shares | Aug. 31, 2021 ft² | Feb. 28, 2021 USD ($) $ / shares shares | Mar. 31, 2018 USD ($) $ / shares shares | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2022
Owners of More Than 5% of Our Common Stock or Board of Directors |  |  |  |  |  |  |  |  |
Sublease income - related party |  |  |  |  |  | $ 147,000 | $ 56,000 | $ 439,000 |
Burlingame, California Office |  |  |  |  |  |  |  |  |
Owners of More Than 5% of Our Common Stock or Board of Directors |  |  |  |  |  |  |  |  |
Area of property subleased | ft² |  | 7,585 |  |  |  |  |  |  |
Sublease income - related party |  |  |  |  | $ 0.0 |  | 100,000 |  |
Angel Pharmaceuticals | Burlingame, California Office |  |  |  |  |  |  |  |  |
Owners of More Than 5% of Our Common Stock or Board of Directors |  |  |  |  |  |  |  |  |
Area of property subleased | ft² |  | 7,585 |  |  |  |  |  |  |
Sublease income - related party |  |  |  |  |  |  | 100,000 | 300,000 |
ICON plc |  |  |  |  |  |  |  |  |
Owners of More Than 5% of Our Common Stock or Board of Directors |  |  |  |  |  |  |  |  |
Clinical trial expense |  |  |  |  |  |  | $ 200,000 | 200,000 |
Follow-on Public Offering |  |  |  |  |  |  |  |  |
Public Offerings |  |  |  |  |  |  |  |  |
Issuance of common stock | shares |  |  | 9,783,660 | 8,117,647 |  |  |  |  |
Share offering price | $ / shares |  |  | $ 3.50 | $ 8.50 |  |  |  |  |
Proceeds from sale of stock |  |  | $ 32,000,000.0 | $ 64,900,000 |  |  |  |  |
Over-Allotment Option |  |  |  |  |  |  |  |  |
Public Offerings |  |  |  |  |  |  |  |  |
Issuance of common stock | shares | 502,618 |  | 1,212,231 | 1,058,823 |  |  |  |  |
Share offering price | $ / shares | $ 15.00 |  |  |  |  |  |  |  |
Angel Pharmaceuticals |  |  |  |  |  |  |  |  |
Related Party Transactions |  |  |  |  |  |  |  |  |
Ownership interest (as percent) |  |  |  |  | 49.70% |  | 49.70% |  | 49.70%
Angel Pharmaceuticals | Angel Pharmaceuticals |  |  |  |  |  |  |  |  |
Related Party Transactions |  |  |  |  |  |  |  |  |
Ownership interest (as percent) |  |  |  |  |  |  |  |  | 49.70%
Owners of More Than 5% of Our Common Stock or Board of Directors |  |  |  |  |  |  |  |  |
Internal personnel costs |  |  |  |  |  |  | $ 0.0 | 140,000 |
Related party research service costs |  |  |  |  | $ 9,000,000,000 |  | 225,000,000,000 |  |
Third-party costs |  |  |  |  |  |  | $ 59,000 | $ 631,000 |

X
- Definition Area of property subleased. + References No definition available. + Details
Name: | crvs_AreaOfPropertySubleased
Namespace Prefix: | crvs_
Data Type: | dtr-types:areaItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of clinical trial expense incurred during the period. + References No definition available. + Details
Name: | crvs_ClinicalTrialExpense
Namespace Prefix: | crvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of internal personnel costs billed to related party during the period. + References No definition available. + Details
Name: | crvs_RelatedPartyInternalPersonnelCosts
Namespace Prefix: | crvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of research service costs billed to related parties during the period. + References No definition available. + Details
Name: | crvs_RelatedPartyResearchServiceCosts
Namespace Prefix: | crvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition n/a + References No definition available. + Details
Name: | crvs_RelatedPartyStockTransactionsAbstract
Namespace Prefix: | crvs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of third party costs billed to related party during the period. + References No definition available. + Details
Name: | crvs_RelatedPartyThirdPartyCosts
Namespace Prefix: | crvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of sublease income in connection with related party transactions. + References No definition available. + Details
Name: | crvs_SubleaseIncomeRelatedParty
Namespace Prefix: | crvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=crvs_AngelPharmaceuticalsCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=crvs_IconPlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=crvs_FollowOnPublicOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=crvs_AngelPharmaceuticalsCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |